Cytek Biosciences Inc (NAS:CTKB)
$ 5.6 0.03 (0.54%) Market Cap: 735.13 Mil Enterprise Value: 479.43 Mil PE Ratio: 0 PB Ratio: 1.87 GF Score: 60/100

Cytek Biosciences Inc at Morgan Stanley Global Healthcare Conference Transcript

Sep 14, 2022 / 03:45PM GMT
Release Date Price: $14.23 (+3.79%)
Tejas Rajeev Savant
Morgan Stanley, Research Division - Equity Analyst

Hey, everyone, good morning. My name is Tejas Savant, and I'm the life science tools and diagnostics analyst at Morgan Stanley. It's my pleasure this morning to host Cytek. And from the company, we have Wenbin and Patrik. Thanks, guys, for doing this. Wenbin, maybe just to set the stage for folks not as familiar with Cytek. Can you just give us a 2-minute introduction to the company, and what is it that you'd highlight as your key accomplishments since IPO?

Questions & Answers

Wenbin Jiang
Cytek Biosciences, Inc. - President, CEO & Chairman of the Board

Sure. And I think Cytek went public last year, since then the company has continued to execute based on what we presented to the investment community to the public. Over the last 12 months, we grew our revenue consistently quarter-by-quarter. And also, one of the differentiation factor for Cytek is we operate the company based on making sure we continue to maintain the company's profitability while keep the growth momentum.

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot